ReviewCurrent drug safety2018
Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature.
Review in Current drug safety, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.Annals of the rheumatic diseases · 2021Guideline
- Exposure-Response Relationship of Dostarlimab in Primary Advanced/Recurrent Endometrial Cancer: Results From Interim Analysis 2 of Part 1 of the RUBY Trial.Clinical pharmacology in drug development · 2026Trial
- Population pharmacokinetics and exposure-response relationships of dostarlimab in primary advanced or recurrent endometrial cancer in part 1 of RUBY.British journal of clinical pharmacology · 2025Trial
- Case Report: Immune checkpoint inhibitor-induced IgG4-related disease mimicking renal metastatic progression: successful steroid-sparing management with rituximab.Frontiers in immunology · 2026Article
- A Case of PMR-Like irAE Developing After Treatment With Ipilimumab and Nivolumab for Lung Cancer.Respirology case reports · 2025Article
- Urgent considerations on renal immune-related adverse events in oncology practice.Frontiers in immunology · 2025Review
- Case Report: Dialysis following sintilimab-induced stage 3 acute kidney injury: mechanism investigation and management strategies.Frontiers in oncology · 2025Article
- Cancer survivors and cancer pain.BJA education · 2024Review
- Organ-specific accuracy of [Japanese journal of radiology · 2024Article
- Immune checkpoint inhibitors and acute kidney injury.Frontiers in immunology · 2024Review
- Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune-related adverse events among cancer patients.Cancer immunology, immunotherapy : CII · 2023Review
- Anti-programmed death-1 inhibitor nivolumab-induced immune-related adverse events: hepatitis, renal insufficiency, myositis, vitiligo, and hypothyroidism: a case-based review.Rheumatology international · 2023Review
- Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy.Frontiers of medicine · 2022Review
- Therapy-induced bone changes in oncology imaging withAnnals of nuclear medicine · 2022Review
- Rheumatological Adverse Events Following Immunotherapy for Cancer.Medicina (Kaunas, Lithuania) · 2022Article
- Frequency of Immune Checkpoint Inhibitor-Induced Vasculitides: An Observational Study Using Data From the Japanese Adverse Drug Event Report Database.Frontiers in pharmacology · 2022Article
- Rheumatic Immune-Related Adverse Events-A Consequence of Immune Checkpoint Inhibitor Therapy.Biology · 2021Review
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.Journal for immunotherapy of cancer · 2021Article
- Synthesis ofVaccines · 2021Article
- Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors.Immunotherapy advances · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmune checkpoint inhibitors are a new promising class of antitumor drugs that have been associated with a number of immune-related Adverse Events (AEs), including musculoskeletal and rheumatic disease.
methodsWe searched Medline reviewing reports of musculoskeletal and rheumatic AEs induced by immune checkpoint inhibitors.
resultsSeveral musculoskeletal and rheumatic AEs associated with immune checkpoint inhibitors treatment are reported in the literature. In particular, arthralgia and myalgia were the most common reported AEs, whereas the prevalence of arthritis, myositis and vasculitis is less characterized and mainly reported in case series and case reports. Other occasionally described AEs are sicca syndrome, polymyalgia rheumatica, systemic lupus erythematosus and sarcoidosis.
conclusionNewly induced musculoskeletal and rheumatic diseases are a frequent adverse event associated with immune checkpoint inhibitors treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.